The Latest Cardiac and Vascular News
Caristo’s AI Technology for Coronary Inflammation Measurement and Risk Assessment Can Transform Risk Stratification and Management of Patients PHILADELPHIA, Nov. 13, 2023 /PRNewswire/ — New research, presented today at the American Heart Association’s Late Breaking Science Sessions, has…
DENVER – November 11, 2023 – Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions. TRANSFORM is a randomized trial – sponsored by Cleerly – that aims to […]
PASADENA, Calif., Nov. 13, 2023 /PRNewswire/ — Ventric Health, a healthcare technology company and medical device provider focused on cardiovascular health, has announced data presented Saturday, November 11, at the American Heart Association (AHA) Scientific Symposium highlighting a pivotal study demonstrating validation of a noninvasive brachial cuff-ECG system for estimation of elevated left ventricular […]
AHA23: Clinics in the U.S. are projected to save more than 400 hours per year using artificial intelligence (AI) applied to LINQ II™ ICMs that reduce false alerts New data presented today at the American Heart Association’s (AHA) Scientific Sessions 2023 show false alert reductions of more than 91% on […]
ANN ARBOR, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the presentation of results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. Results were also simultaneously published in Circulation which can be accessed here. “The analysis presented at AHA and […]
Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd […]
Collaboration will harness the potential of non coding RNAs (ncRNAs) in regenerating heart tissue Ethris will contribute its proprietary SNaP LNP platform for precise ncRNA delivery while Heqet Therapeutics will lead preclinical and clinical development Ethris to receive milestone and royalty payments, highlighting the commitment of both companies to advance […]
WASHINGTON–(BUSINESS WIRE)– #ML–CorVista Health, Inc., a leading digital health company dedicated to improving cardiovascular disease diagnosis, is pleased to announce the presentation of Machine Learning to Detect Pulmonary Hypertension data at AHA. “We are pleased to present this important data at this year’s AHA meeting.” said Don Crawford, President and CEO of CorVista Health. “Pulmonary hypertension is a challenging condition to diagnose, especially early in the disease progression. This pres
New Repatha® (evolocumab) Data Show No Decline in Cognitive Function Associated With Very Low Levels of LDL-C Olpasiran Research Provides Further Insights Into Cardiovascular Risks Associated With Elevated Lp(a) Amgen Provides Updates on Efforts to Advance Bold Ambition of Halving the…
ATLANTA, Nov. 9, 2023 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed enrollment in the PERSEVERE clinical trial. The PERSEVERE trial is a prospective, multicenter, non-randomized…
